BOSTON– AACR-NCI-EORTC - November 6, 2015—Biodesix, Inc., today announced that its data on genomic and proteomic blood-based diagnostic assays will be presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. These blood-based diagnostic tests for patients with non-small cell lung cancer (NSCLC) are developed with a focus on results within 72 hours of the patient’s blood being drawn so that clinicians can make treatment decisions sooner. The data will be presented as three posters.
Lung cancer is the leading cause of cancer death in the U.S., but diagnostic testing in lung cancer faces certain limitations when relying on traditional tissue biopsies. Tissue biopsy is either unavailable or insufficient for up to one-third of lung cancer patients; such biopsies can also present health risks for certain patients. In these three posters, Biodesix assesses data from minimally invasive, highly sensitive blood-based tests that offer quick results.
Poster title: Comparative assessment of MALDI-TOF platforms for utility in CDx development of a proteomic signature for ficlatuzumab in patients with NSCLC
Authors: Nicholas Dupuis, Maximillian Steers; Amanda Weaver; Zhigang Weng (AVEO Oncology); Francis Payumo, (AVEO Oncology); Michael Needle (AVEO Oncology); Gary Pestano.
Assessing the proteomic signature of a given cancer has the potential to give clinicians a better understanding of the cancer’s current microenvironment. As part of the FOCAL Phase 2 clinical trial, being conducted in partnership with AVEO Oncology, a matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry based serum proteomics companion diagnostic test, BDX004, is currently under development. Within the FOCAL trial, the test will be used to select previously untreated, EGFR mutation-positive patients for one of two treatment groups. Biodesix and AVEO Oncology will present data from a comparative assessment of the clinical utility of three MALDI-TOF platforms for the measurement of eight serum protein variants.
This poster (#B128) will be presented on Saturday, Nov 7 from 12:30-3:30 pm in Halls C-D.
Poster title: Rapid blood-based test for ALK, RET and ROS1 mRNA fusions and somatic variants in NSCLC
Authors: Hestia Mellert, Kristina Koch, Shannon Campbell, Gary Pestano
Detection of mRNA fusions in tumors can be an important prognostic for the therapeutic response of patients with NSCLC. Typically, these fusions are assessed using tissue based fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) methodologies. Many NSCLC patients, however, may not be good candidates for tissue biopsies. Data will be presented for blood-based detection of circulating mRNA fusion transcripts for ALK, RET, and ROS1 in just 72 hours.
This poster (#C148) will be presented on Sunday, Nov 8th from 12:30-3:30 pm in Halls C-D.
Poster title: Development of a rapid blood-based test for EGFR sensitizing and resistance mutations in NSCLC
Authors: Trudi Foreman, Kristina Koch, Amanda Weaver, Nicholas Dupuis, Steven Arrivo, Ubaradka Sathyanarayana, Hestia Mellert, Gary Pestano
Although tumor biopsies are a gold standard for making therapeutic decisions, the time to results is lengthy and this procedure is invasive. Blood-based biopsies that identify EGFR sensitizing mutations, represent a rapid, non-invasive diagnostic for identifying patients who could benefit from tyrosine kinase inhibitors (TKIs). Biodesix will present data for blood based droplet digital PCR assays for the detection of two sensitizing EGFR mutations (L858R and exon 19 deletion E746-A750) as well as for monitoring of the EGFR resistance mutation (T790M). These assays can provide results to physicians within 72 hours and may therefore facilitate more immediate patient management.
This poster (#B137) will be presented on Saturday, Nov 7th from 12:30-3:30 pm in Halls C-D.
The International Conference on Molecular Targets and Cancer Therapeutics is an annual meeting hosted by the American Association of Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC). Over 3,000 international research scientists, clinicians, and pharmaceutical representatives are expected to gather at this year’s conference to exchange the latest research and innovations in cancer biomarker detection, monitoring of resistance development, and development of targeted therapeutics.
Biodesix, VeriStrat and GeneStrat are trademarks or registered trademarks of Biodesix, Inc. All other trademarks mentioned herein are the property of their respective owners.
Biodesix® is a molecular diagnostics company advancing the development of innovative blood-based tests – GeneStrat™ and VeriStrat® - in oncology for precision medicine. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, which can lead to improved patient outcomes. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic tests on various discovery platforms. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents.
About AVEO Oncology
AVEO Oncology (NASDAQ: AVEO) is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform™ provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. For more information, please visit the company’s website at www.aveooncology.com.